---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000123"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:18:17.241522+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis

## Summary
- 100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
- No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.
- Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.
- Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.
- Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation.

## SEC filing metadata
- accession: 0001453687-25-000123
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/0001453687-25-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/rnac-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000123
- JSON: https://secwatch.observer/filing/0001453687-25-000123.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.